Reproductive Potential News Today

Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver

The National Lipid Association Scientific Sessions will be held Thursday to Sunday and will spotlight emerging areas of research such as “cardio-rheumatology,” a renewed push to reinstate LDL as a health system quality metric and more. Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, chief of the section of cardiovascular research and professor of medicine at Baylor College of

ENHERTU demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of...

Daiichi Sankyo and AstraZeneca’s ENHERTU also demonstrated a clinically meaningful progression-free survival improvement in patients with HER2 ultralow expression Plans for global regulatory...

First non-immunosuppressive therapy for the treatment of IgA nephropathy approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful...

DURHAM, N.C.--(BUSINESS WIRE)--Apr 8, 2024--

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--

Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease SAN DIEGO,...

Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally...

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and...